Sign inJoin waitlistJoin the waitlist

David Bushnell

Professor of Radiology - Division of Nuclear Medicine · Roy J. and Lucille A. Carver College of Medicine

Credentials: · · · ·

History

Roy J. and Lucille A. Carver College of Medicine
Present

Nuclear Medicine
University of Wisconsin Hospitals and Clinics
1982–1985
Internal Medicine
Advocate Lutheran General Hospital
1979–1982
University of Illinois at the Medical Center College of Medicine
1975–1979

Research

Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
New England Journal of Medicine · 2017 · 2,601 citations
NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas
Pancreas · 2010 · 411 citations
The NANETS consensus guideline for the diagnosis and management of neuroendocrine tumors: well-differentiated neuroendocrine tumors of the Jejunum, Ileum, Appendix, and Cecum
Pancreas · 2010 · 406 citations

Yusuf Menda
23 papers
SO
Sue O’Dorisio
15 papers
TO
Thomas O’Dorisio
15 papers
Daniel Kahn
14 papers · 1 as a fellow
Michael Graham
8 papers
JS
Jonathan Strosberg
6 papers
Matthew Kulke
5 papers
Ali Keshavarzian
4 papers
Andrew Hendifar
4 papers
Edward Wolin
4 papers
James Yao
4 papers
Joseph Dillon
4 papers

Grants

Neuroendocrine Tumor Specialized Programs of Research Excellence (SPORE) in Human Cancer
National Cancer Institute · P50
Project lead · $1.5M · University of Iowa
2015–2022
Dosimetry in Children and Young Adults with Neuroblastoma or Neuroendocrine Tumor
National Cancer Institute · R21
PI · $615.3K · University of Iowa
2008–2012

Clinical trials

A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
Principal investigator · Active not recruiting · Early phase 1
David Bushnell
2023–2027
A Clinical Trial Evaluating the Safety of Combining Lutathera(R) and Azedra(R) to Treat Mid-gut Neuroendocrine Tumors
Principal investigator · Withdrawn · Phase 1, Phase 2
David Bushnell
2022–2024
Combination Targeted Radiotherapy in Neuroendocrine Tumors
Principal investigator · Completed
David Bushnell
2006–2015
Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors
Study chair · Active not recruiting · Early phase 1
David Bushnell
2017–2027